See more : Landcadia Holdings III, Inc (LCYAU) Income Statement Analysis – Financial Results
Complete financial analysis of Covetrus, Inc. (CVET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Covetrus, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- Thomasville Bancshares, Inc. (THVB) Income Statement Analysis – Financial Results
- SIL Investments Limited (SILINV.NS) Income Statement Analysis – Financial Results
- Hangzhou Seck Intelligent Technology Co.,Ltd. (300897.SZ) Income Statement Analysis – Financial Results
- BankInvest – Emerging Markets Obligationer Lokalvaluta (BAIEMOLVA.CO) Income Statement Analysis – Financial Results
- Jiangsu Azure Corporation (002245.SZ) Income Statement Analysis – Financial Results
Covetrus, Inc. (CVET)
About Covetrus, Inc.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine. As of October 13, 2022, Covetrus, Inc. was taken private.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.58B | 4.34B | 3.98B | 3.78B | 3.58B | 3.35B | 2.98B |
| Cost of Revenue | 3.72B | 3.54B | 3.23B | 3.09B | 2.93B | 2.73B | 2.45B |
| Gross Profit | 858.00M | 798.00M | 749.00M | 684.11M | 652.03M | 619.91M | 530.02M |
| Gross Profit Ratio | 18.75% | 18.39% | 18.84% | 18.11% | 18.21% | 18.49% | 17.80% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 881.00M | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 881.00M | 867.00M | 808.00M | 538.47M | 516.70M | 488.82M | 417.87M |
| Cost & Expenses | 4.60B | 4.41B | 4.04B | 3.63B | 3.44B | 3.22B | 2.87B |
| Interest Income | 0.00 | 1.00M | 7.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 32.00M | 47.00M | 56.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 200.00M | 190.00M | 176.00M | 64.10M | 59.05M | 55.45M | 50.30M |
| EBITDA | 178.00M | 211.00M | -794.00M | 201.99M | 171.43M | 153.68M | 134.89M |
| EBITDA Ratio | 3.89% | 4.86% | -19.97% | 5.35% | 4.79% | 4.58% | 4.53% |
| Operating Income | -22.00M | -69.00M | -997.00M | 137.10M | 135.32M | 123.83M | 103.81M |
| Operating Income Ratio | -0.48% | -1.59% | -25.08% | 3.63% | 3.78% | 3.69% | 3.49% |
| Total Other Income/Expenses | -32.00M | 45.00M | -32.00M | 6.08M | 3.45M | 2.97M | 4.69M |
| Income Before Tax | -54.00M | -24.00M | -1.03B | 143.18M | 138.77M | 126.79M | 108.50M |
| Income Before Tax Ratio | -1.18% | -0.55% | -25.88% | 3.79% | 3.88% | 3.78% | 3.64% |
| Income Tax Expense | 32.00M | -7.00M | -7.00M | 37.03M | 48.02M | 27.94M | 24.27M |
| Net Income | -86.00M | -19.00M | -1.02B | 100.86M | 64.35M | 70.30M | 60.32M |
| Net Income Ratio | -1.88% | -0.44% | -25.63% | 2.67% | 1.80% | 2.10% | 2.03% |
| EPS | -0.63 | -0.16 | -9.52 | 0.91 | 0.58 | 0.63 | 0.54 |
| EPS Diluted | -0.63 | -0.16 | -9.52 | 0.91 | 0.58 | 0.63 | 0.54 |
| Weighted Avg Shares Out | 137.00M | 118.00M | 107.00M | 111.19M | 111.19M | 111.19M | 111.19M |
| Weighted Avg Shares Out (Dil) | 137.00M | 118.00M | 107.00M | 111.19M | 111.19M | 111.19M | 111.19M |
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
CD&R, TPG Take Covetrus Private In $4B Deal
Covetrus going private in $4 billion deal
Covetrus to Be Taken Private for $4 Billion
Covetrus Gets Private-Equity Buyout Offer at $21 a Share
Covetrus (CVET) Q1 Earnings Surpass Estimates
Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information
Covetrus, Inc. (CVET) CEO Ben Wolin on Q4 2021 Results - Earnings Call Transcript
Covetrus (CVET) Q4 Earnings Surpass Estimates
Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021
Source: https://incomestatements.info
Category: Stock Reports